Jubilant Cadista Pharmaceuticals, Inc. is recalling 38,160 bottles of Irbesartan (75mg and 150mg), a medication used to treat high blood pressure and kidney disease in patients with type 2 diabetes. The recall was initiated because the tablets failed dissolution specifications, meaning they may not dissolve properly in the body. The products were manufactured in India and distributed to pharmacies nationwide across the United States.
If the medication fails to dissolve as designed, the patient may not receive the intended therapeutic dose. This could lead to poorly controlled blood pressure or inadequate treatment of kidney issues. No incidents or injuries have been reported to date regarding this issue.
You have 2 options:
Recall #: D-1293-2022; Manufactured by Jubilant Generics Ltd. Roorkee, India.
Recall #: D-1294-2022; Manufactured by Jubilant Generics Ltd. Roorkee, India.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.